Evidence map›Paper›PMID 12717832›Full record

ArticleWorld journal of gastroenterology2003

Effect of arsenic trioxide on rat hepatocellular carcinoma and its renal cytotoxity.

Shao-Shan Wang, Ti Zhang, Xi-Lu Wang, Li Hong, Qing-Hui Qi

Open access · hybridAbstract readComparative Study
In one paragraph

Article in World journal of gastroenterology, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 22 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Shao-Shan WangDepartment of Surgery of Dagang Hospital 300270, Tianjin, China. wsss@public.tpt.tj.cn
Ti Zhang
Xi-Lu Wang
Li Hong
Qing-Hui Qi
Tianjin Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimTo study the effect of arsenic trioxide (As(2)O(3)) on rat experimental hepatocellular carcinoma and its renal cytotoxicity.

methodsThe hepatocellular carcinoma model was established by diethaylnitrosamine perfusion in stomach of 120 Wistar rats, and the treatment began at the end of 20 weeks. Before the treatment, the rat models were randomly divided into 5 groups. In the treatment groups, three doses of As(2)O(3) were injected into rat abdominal cavity; the total time of drug administration was 4 weeks. Cisplatin control or the blank group was injected into abdominal cavity with equal amount of cisplatin or saline at the same time, respectively. On the 7th, 14th and 28th day after the treatment, the hepatocellular carcinoma nodules were obtained and the morphologic changes of hepatocellular carcinoma cells were observed under light and electron microscopes; Immunohistochemistry (S-P methods) was employed to detect the expression of bcl-2, bax and PCNA in hepatocellular carcinoma tissues; flow cytometry (TUNEL assay) was used to detect the apoptosis of liver cancer cells and the change of cytokinetics. On the 28th day, the renal was obtained and its histologic change was observed under light microscope, and immunohistochemistry (SP stain) was also employed to detect the expression of bcl-2 and PCNA. Cisplatin and saline solution were used as the control.

resultsAs(2)O(3) could induce the apoptosis of rat liver cancer cells and exhibited typical morphologic changes. The incidence of apoptosis of hapatocellular carcinoma cells was elevated (P=0.001). The elevation was higher in the group of middle-dose of As(2)O(3) (1 mg/kg(-1)) significantly than the other arsenic groups and the controls (P=0.001). Large dose of As(2)O(3) (5 mg/kg(-1)) was able to arise the incidence of apoptosis, but also produced a large amount of necrosis and inflammatory reaction. Middle dose of As(2)O(3) dramatically increased the cell number in G2/M phase (P=0.0001), and apoptosis happened apparently. The expression of bcl-2 and bax was related to the dose of As(2)O(3). With the up-regulation of apoptotic incidence, the ratio of bcl-2/bak decreased. But the incidence of apoptosis was not the highest status and the ratio of bcl-2/bax was at the lowest when the highest-dose of As(2)O(3) was used. There was significant difference among the PCNA indexes (PCNA LI) of the five groups. Of them, three arsenic groups all showed decrease of different degrees, and this down-regulation was most obvious in group A. There was significant difference among the three groups (P=0.016). Under the light microscope, the rat kidney in the cisplatin group exhibited tubular epithelium swelling and degeneration, protein casts in collecting tubules; While all arsenic groups didn't show the significant changes (P=0.013). In the arsenic groups, the expression of bcl-2 in the renal tubular epithelium was increased (P=0.005), no obvious changes happened to PCNA LI. But in the group of cisplatin, the PCNA LI increased significantly (P=0.001).

conclusionAs(2)O(3) can induce apoptosis of rat hepatocellular carcinoma cells. And there is optimum dose; too high dose will induce the cytotoxic effect, while certain dose of As(2)O(3) is able to block the cell cycle at G2/M phase. As(2)O(3) had the most remarkable influence on G2/M cells, and it can also induce apoptosis to cells at other phases. As(2)O(3) can restrain the proliferation of rat hepatocellular carcinoma cells, in a dose-time dependent manner; Compared with cisplatin, As(2)O(3) didn't show obvious renal toxicity, which was related to the increasing expression of bcl-2 in renal tubular epithelium, the inhibition of apoptosis and the anti-oxidation effects.

Indexed as

AnimalsAntineoplastic AgentsApoptosisArsenicalsArsenic TrioxideCell DivisionCisplatinFemaleImmunohistochemistryKidneyLiver Neoplasms, ExperimentalMaleOxidesProliferating Cell Nuclear AntigenProto-Oncogene Proteins c-bcl-2RatsAntineoplastic AgentsArsenicalsArsenic TrioxideCisplatinOxidesProliferating Cell Nuclear AntigenProto-Oncogene Proteins c-bcl-2

Identifiers

PMID12717832
PMCPMC4611399
OpenAlexW2415938891

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.